HK1178538A1 - 氧-取代的 -雜芳酰基氨基-丙酸衍生物及其藥物用途 - Google Patents
氧-取代的 -雜芳酰基氨基-丙酸衍生物及其藥物用途Info
- Publication number
- HK1178538A1 HK1178538A1 HK13106299.0A HK13106299A HK1178538A1 HK 1178538 A1 HK1178538 A1 HK 1178538A1 HK 13106299 A HK13106299 A HK 13106299A HK 1178538 A1 HK1178538 A1 HK 1178538A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- heteroaroylamino
- pharmaceuticals
- substituted
- oxygen
- propionic acid
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C229/34—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
- C07C229/36—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton containing six-membered aromatic rings with at least one amino group and one carboxyl group bound to the same carbon atom of the carbon skeleton
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/18—One oxygen or sulfur atom
- C07D231/20—One oxygen atom attached in position 3 or 5
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/18—One oxygen or sulfur atom
- C07D231/20—One oxygen atom attached in position 3 or 5
- C07D231/22—One oxygen atom attached in position 3 or 5 with aryl radicals attached to ring nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Neurosurgery (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Urology & Nephrology (AREA)
- Pulmonology (AREA)
- Hospice & Palliative Care (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Emergency Medicine (AREA)
- Obesity (AREA)
- Psychiatry (AREA)
- Endocrinology (AREA)
- Vascular Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP10305080 | 2010-01-26 | ||
US30911910P | 2010-03-01 | 2010-03-01 | |
PCT/EP2011/051038 WO2011092187A1 (en) | 2010-01-26 | 2011-01-26 | Oxygen-substituted 3-heteroaroylamino-propionic acid derivatives and their use as pharmaceuticals |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1178538A1 true HK1178538A1 (zh) | 2013-09-13 |
Family
ID=42035666
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK13106299.0A HK1178538A1 (zh) | 2010-01-26 | 2013-05-28 | 氧-取代的 -雜芳酰基氨基-丙酸衍生物及其藥物用途 |
Country Status (30)
Country | Link |
---|---|
US (2) | US8664257B2 (zh) |
EP (2) | EP2826772A1 (zh) |
JP (1) | JP5736390B2 (zh) |
KR (1) | KR101764608B1 (zh) |
CN (1) | CN102884052B (zh) |
AR (1) | AR079967A1 (zh) |
AU (1) | AU2011209333B2 (zh) |
BR (1) | BR112012018253A2 (zh) |
CA (1) | CA2784571A1 (zh) |
CL (1) | CL2012002069A1 (zh) |
CO (1) | CO6660462A2 (zh) |
DK (1) | DK2528902T3 (zh) |
ES (1) | ES2530073T3 (zh) |
HK (1) | HK1178538A1 (zh) |
HR (1) | HRP20150075T1 (zh) |
IL (1) | IL220998A0 (zh) |
MA (1) | MA33948B1 (zh) |
MX (1) | MX2012008635A (zh) |
MY (1) | MY156569A (zh) |
NZ (1) | NZ601307A (zh) |
PL (1) | PL2528902T3 (zh) |
PT (1) | PT2528902E (zh) |
RS (1) | RS53789B1 (zh) |
RU (1) | RU2561126C2 (zh) |
SG (1) | SG182659A1 (zh) |
SI (1) | SI2528902T1 (zh) |
TW (1) | TWI532725B (zh) |
UY (1) | UY33200A (zh) |
WO (1) | WO2011092187A1 (zh) |
ZA (1) | ZA201204414B (zh) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105017187B (zh) | 2009-07-08 | 2017-10-24 | 德米拉(加拿大)公司 | 用于治疗皮肤病症或疾病状态的tofa类似物 |
CA2835216A1 (en) * | 2011-05-31 | 2012-12-06 | Theravance, Inc. | Neprilysin inhibitors |
CN103582630B (zh) | 2011-05-31 | 2016-08-17 | 施万生物制药研发Ip有限责任公司 | 脑啡肽酶抑制剂 |
US8686184B2 (en) | 2011-05-31 | 2014-04-01 | Theravance, Inc. | Neprilysin inhibitors |
KR20140049019A (ko) * | 2011-07-26 | 2014-04-24 | 사노피 | 3―헤테로아로일아미노―프로피온산 유도체 및 이의 약제로서의 용도 |
WO2013014205A1 (en) * | 2011-07-26 | 2013-01-31 | Sanofi | Substituted 3 - (thiazole - 4 - carbonyl) - or 3 - (thiazole - 2 - carbonyl) aminopropionic acid derivatives and their use as pharmaceuticals |
JO3215B1 (ar) | 2012-08-09 | 2018-03-08 | Phenex Pharmaceuticals Ag | حلقات غير متجانسة بها 5 ذرات تحتوي على النيتروجين بها استبدال بكربوكساميد أو سلفوناميد كمعدلات لمستقبل نووي غير محمي RORy |
WO2014053533A1 (en) | 2012-10-05 | 2014-04-10 | Sanofi | Use of substituted 3-heteroaroylamino-propionic acid derivatives as pharmaceuticals for prevention/treatment of atrial fibrillation |
SG11201506190QA (en) * | 2013-03-28 | 2015-09-29 | Sanofi Sa | Biaryl-propionic acid derivatives and their use as pharmaceuticals |
EP2978747B1 (en) | 2013-03-28 | 2017-04-19 | Sanofi | Biaryl-propionic acid derivatives and their use as pharmaceuticals |
JPWO2015060368A1 (ja) | 2013-10-23 | 2017-03-09 | 武田薬品工業株式会社 | 複素環化合物 |
RU2719599C2 (ru) | 2016-02-23 | 2020-04-21 | Пфайзер Инк. | Соединения 6, 7-дигидро-5H-пиразоло[5,1-b][1,3]оксазин-2-карбоксамида |
Family Cites Families (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE226883C (de) | 1908-12-03 | 1910-10-11 | Draegerwerk Ag | UEberdruckoperationsapparat, bei welchem der Lunge des Patienten durch Mund und Nase die Atmungsluft unter moeglichst gleichbleibenden, geringem UEberdruck zugefuehrt wird |
DD226883A1 (de) | 1984-07-30 | 1985-09-04 | Neubauer T Paedagog Hochschule | Verfahren zur herstellung von 1,3-disubstituierten 5-alkoxy-1,2,4-triazolen und 1,2,4-triazolin-5-onen |
US5258397A (en) | 1988-11-30 | 1993-11-02 | Novapharme | 3-Isoxazoyl derivatives endowed with anticonvulsant activity, procedure for their preparation and their pharmaceutical compositions |
SG49073A1 (en) | 1993-05-27 | 1998-05-18 | Shell Int Research | Herbicidal thiazole derivatives |
JP2000169453A (ja) | 1998-09-30 | 2000-06-20 | Mitsubishi Chemicals Corp | 1―フェニルピラゾ―ル―3―カルボキサミド誘導体、その中間体およびこれを有効成分とする農薬 |
US20020173507A1 (en) | 2000-08-15 | 2002-11-21 | Vincent Santora | Urea compounds and methods of uses |
US20040072802A1 (en) | 2002-10-09 | 2004-04-15 | Jingwu Duan | Beta-amino acid derivatives as inhibitors of matrix metalloproteases and TNF-alpha |
WO2004056815A1 (en) | 2002-12-23 | 2004-07-08 | Aventis Pharma Deutschland Gmbh | PYRAZOLE-DERIVATIVES AS FACTOR Xa INHIBITORS |
JP2005145839A (ja) | 2003-11-12 | 2005-06-09 | Japan Science & Technology Agency | 新規なカテプシンa阻害剤 |
BRPI0513677B8 (pt) * | 2004-07-30 | 2021-05-25 | Exelixis Inc | derivados de pirrol como agentes farmacêuticos |
WO2006076202A1 (en) | 2005-01-10 | 2006-07-20 | Exelixis, Inc. | Heterocyclic carboxamide compounds as steroid nuclear receptors ligands |
US20090209522A1 (en) | 2005-06-28 | 2009-08-20 | Graham Andrew Showell | Heterocyclic Non-Peptide GNRH Antagonists |
CN101104602A (zh) * | 2006-07-12 | 2008-01-16 | 赛诺菲-安万特 | N-[(1,5-二苯基-1h-吡唑-3-基)甲基]磺酰胺衍生物其制备、用途 |
FR2908409B1 (fr) * | 2006-11-10 | 2009-01-09 | Sanofi Aventis Sa | Pyrazoles substituees,compositions les contenant,procede de fabrication et utilisation |
TW200904433A (en) | 2007-04-27 | 2009-02-01 | Takeda Pharmaceutical | Substituted imidazole compound and use thereof |
MX2010006109A (es) * | 2007-12-10 | 2010-09-10 | 7Tm Pharma As | Moduladores de receptores de canabinoides. |
JP5560202B2 (ja) | 2007-12-26 | 2014-07-23 | サノフイ | P2y12拮抗薬としてのピラゾール−カルボキサミド誘導体 |
EP2238128B1 (en) | 2007-12-26 | 2012-08-22 | Sanofi | Heterocyclic pyrazole-carboxamides as p2y12 antagonists |
RU2010138640A (ru) | 2008-02-21 | 2012-03-27 | Актелион Фармасьютиклз Лтд (Ch) | Производные 2-аза-бицикло [2.2.1] гептана |
KR101442897B1 (ko) * | 2009-05-28 | 2014-09-23 | 노파르티스 아게 | 네프릴리신 억제제로서의 치환된 아미노프로피온산 유도체 |
-
2011
- 2011-01-24 AR ARP110100220A patent/AR079967A1/es unknown
- 2011-01-24 TW TW100102413A patent/TWI532725B/zh not_active IP Right Cessation
- 2011-01-24 UY UY0001033200A patent/UY33200A/es not_active Application Discontinuation
- 2011-01-26 MY MYPI2012002853A patent/MY156569A/en unknown
- 2011-01-26 JP JP2012550422A patent/JP5736390B2/ja not_active Expired - Fee Related
- 2011-01-26 MA MA35095A patent/MA33948B1/fr unknown
- 2011-01-26 PL PL11701123T patent/PL2528902T3/pl unknown
- 2011-01-26 RU RU2012136473/04A patent/RU2561126C2/ru not_active IP Right Cessation
- 2011-01-26 ES ES11701123.9T patent/ES2530073T3/es active Active
- 2011-01-26 BR BR112012018253A patent/BR112012018253A2/pt not_active IP Right Cessation
- 2011-01-26 US US13/575,008 patent/US8664257B2/en not_active Expired - Fee Related
- 2011-01-26 CA CA2784571A patent/CA2784571A1/en not_active Abandoned
- 2011-01-26 EP EP20140187399 patent/EP2826772A1/en not_active Withdrawn
- 2011-01-26 PT PT117011239T patent/PT2528902E/pt unknown
- 2011-01-26 SG SG2012054185A patent/SG182659A1/en unknown
- 2011-01-26 CN CN201180016053.7A patent/CN102884052B/zh not_active Expired - Fee Related
- 2011-01-26 SI SI201130368T patent/SI2528902T1/sl unknown
- 2011-01-26 MX MX2012008635A patent/MX2012008635A/es active IP Right Grant
- 2011-01-26 AU AU2011209333A patent/AU2011209333B2/en not_active Ceased
- 2011-01-26 NZ NZ601307A patent/NZ601307A/en not_active IP Right Cessation
- 2011-01-26 DK DK11701123.9T patent/DK2528902T3/en active
- 2011-01-26 KR KR1020127022317A patent/KR101764608B1/ko active IP Right Grant
- 2011-01-26 WO PCT/EP2011/051038 patent/WO2011092187A1/en active Application Filing
- 2011-01-26 EP EP11701123.9A patent/EP2528902B1/en not_active Not-in-force
- 2011-01-26 RS RS20150053A patent/RS53789B1/en unknown
-
2012
- 2012-06-15 ZA ZA2012/04414A patent/ZA201204414B/en unknown
- 2012-07-17 IL IL220998A patent/IL220998A0/en not_active IP Right Cessation
- 2012-07-25 CO CO12124759A patent/CO6660462A2/es active IP Right Grant
- 2012-07-25 CL CL2012002069A patent/CL2012002069A1/es unknown
-
2013
- 2013-05-28 HK HK13106299.0A patent/HK1178538A1/zh not_active IP Right Cessation
-
2014
- 2014-01-10 US US14/151,951 patent/US20140128616A1/en not_active Abandoned
-
2015
- 2015-01-20 HR HRP20150075AT patent/HRP20150075T1/hr unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HUS2100032I1 (hu) | Helyettesített 5-fluor-1H-pirazolopiridin-származékok és alkalmazásuk | |
IL250259B (en) | Preparations containing ursolic acid or its derivative and their uses | |
HK1192879A1 (zh) | 取代的 -苄基環烷基羧酸及其用途 | |
HK1178538A1 (zh) | 氧-取代的 -雜芳酰基氨基-丙酸衍生物及其藥物用途 | |
IL221511A (en) | Arilatriazolones associated with bis aryl and their use | |
ZA201208173B (en) | Peptices and their use | |
IL250370A0 (en) | Propionic acid derivatives substituted with heteroaroylamino in position 3 and their use as pharmaceuticals | |
ZA201303773B (en) | Compounds and their use | |
EP2575453A4 (en) | OLIGO-BENZAMIDE COMPOUNDS AND THEIR USE | |
PL2521445T3 (pl) | Preparat i jego zastosowanie | |
EP2636666A4 (en) | TRANS-2 DECENTRIC ACID DERIVATIVES AND MEDICAMENTS CONTAINING THEREOF | |
PL2648715T3 (pl) | Mieszaniny karnozyny-kwasu hialuronowego i ich zastosowanie | |
ZA201205684B (en) | Ester compound and use thereof | |
GB201020848D0 (en) | Compounds and their use | |
GB201018028D0 (en) | Compounds and their use | |
GB201017822D0 (en) | Compounds and their use | |
GB201005511D0 (en) | Compounds and their use | |
GB201002337D0 (en) | Compounds and their use | |
GB201000305D0 (en) | Compounds and their use | |
GB201000308D0 (en) | Compounds and their use | |
GB201000309D0 (en) | Compounds and their use | |
GB201000307D0 (en) | Compounds and their use | |
GB201005729D0 (en) | End effectors and parts thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PC | Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee) |
Effective date: 20190121 |